Zobrazeno 1 - 10
of 23
pro vyhledávání: ''
Autor:
Erich Rajkovic, Stefan Knackmuss, Torsten Haneke, Michael Tesar, Wolfgang Fischer, Ute Schniegler-Mattox, Ivica Fucek, Uwe Reusch, Susanne Wingert, Michael Damrat, Kristina Ellwanger, Thomas Mueller, Andras Strassz
Publikováno v:
Cancer Research. 80:5659-5659
The epidermal growth factor receptor (EGFR) is a prime target for cancer therapy across many solid tumor types, including CRC, NSCLC, breast, esophageal cancer, and SCCHN. Binding of EGFR by its ligand EGF induces cell proliferation, a process which
Autor:
Ekkehard Moessner, Pablo Umana, Sylvia Herter, Christian Gerdes, Birgit Bossenmaier, Carola Ries, Michaela Roemmele, Nicolini Valeria G, Hans Joachim Mueller, Thomas Friess, Olivier Freytag, Erwin van Puijenbroek, Sabine Lang
Publikováno v:
Clinical Cancer Research. 19:1126-1138
Purpose: Anti-EGF receptor (EGFR) antibodies and small-molecule tyrosine kinase inhibitors have shown activity in epithelial tumors; however, agents that work by blocking the EGFR growth signal are ineffective when the oncogenic stimulus arises downs
Autor:
Marc Ladanyi, Ronglai Shen, Maureen F. Zakowski, Naiyer A. Rizvi, Bernard J. Park, Mark G. Kris, Jamie E. Chaft, Robert T. Heelan, Christopher G. Azzoli, Raja M. Flores, William Pao, Bhuvanesh Singh, Manjit S. Bains, Vincent A. Miller, Valerie W. Rusch, Lee M. Krug, Robert J. Downey
Publikováno v:
Clinical Cancer Research. 17:3500-3506
Purpose: To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). Patients and Methods: Patients with resectable stage I and II non–small c
Autor:
Peter L. Choyke, Liqiang Xi, Jeremy Force, Corrine Keen, Mark Raffeld, Martin Gutierrez, Ariel Lopez-Chavez, Baris Turkbey, Liang Cao, Ronan J. Kelly, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Yunkai Yu, Arun Rajan, Giuseppe Giaccone
Publikováno v:
Clinical Cancer Research. 17:1190-1199
Purpose: Sorafenib, a multikinase inhibitor targeting Raf and VEGFR, has shown activity in unselected patients with non–small-cell lung cancer (NSCLC). At present there are no validated biomarkers indicative of sorafenib activity. Experimental Desi
Autor:
Erik Vassella
Publikováno v:
Cancer Research. 78:2370-2370
Background: Epidermal growth factor receptor (EGFR) mutations enable constitutive active downstream signaling of PI3K/AKT, KRAS/ERK and JAK/STAT pathways, and promote tumor progression by inducing uncontrolled proliferation, evasion of apoptosis and
Autor:
Zhiquan Wang, Erin E. Tapper, Qian Nie, Phillip A. Kubica, Steven M. Offer, Kelly J. Bouchonville, Colbren S. Trogstad-Isaacson, Calvin R. Jerde, Shikshya Shrestha, Rentian Wu, Robert B. Diasio
Publikováno v:
Cancer Research. 78:911-911
Colorectal cancer (CRC) is the third most common cancer and is expected to cause approximately 50,000 deaths in the US in 2017. The antimetabolite 5-fluorouracil (5-FU) is the cornerstone of first-line adjuvant chemotherapy regimens for CRC. Resistan
Publikováno v:
Clinical Cancer Research. 15:7502-7509
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and are approved around the world for the treatment of patients with non-small cell lung cancer (NSCLC). Somatic mutations in the EG
Autor:
Qiping Zhao, Gilbert A. Keller, Dan C. Maneval, Steve Rowe, Chunmei Zhao, Kim Phan, Michael Shepard, Ryan J. Osgood, Robert J. Connor, Lei Huang, Xiaoming Li, Gregory I. Frost, Curtis B. Thompson, Jason Parise, Sanna Rosengren, Christopher D. Thanos, Ge Wei, Jessica Cowell, Bob Veneziale
Publikováno v:
Cancer Research. 76:B32-B32
The epidermal growth factor (EGF) signaling pathway relies on recognition by its receptor, EGFR, and subsequent downstream signaling by the KRAS and BRAF proteins to relay proper proliferative, migratory, and angiogenic functions. Cancers with activa
Autor:
Ashok Srinivasan, James L. Wade, Thomas J. George, Marc Buyse, Jodi A. Kanyuch, Ashwin Reddy Sama, Norman Wolmark, S. Rim Kim, Ding Wang, Kay L. Pogue-Geile, James J. Lee, Samuel A. Jacobs, Philip J. Stella, Carmen J. Allegra
Publikováno v:
Molecular Cancer Therapeutics. 14:C46-C46
Background Multiple mechanisms may account for de novo and acquired resistance to Cmab. One mechanism, HER2 amplification, promotes heterodimer formation with HER3, bypassing EGFR blockade and resulting in downstream signaling. Bertotti reported HER2
Autor:
Mahnaz Darvish-Damavandi, Giulia Mentrast, Sarah Barton, Ian Chau, David Watkins, Sheela Rao, Khurum Khan, Naureen Starling, George Vlachogianis, David Cunningham, Nicola Valeri, Andrea Lampis, Ruwaida Begum, Francesco Trevisani, Chiara Braconi, Jens C. Hahne, Nasir Khan, Clare Peckitt, Annette Bryant
Publikováno v:
Cancer Research. 75:3589-3589
Background: AE-mABs (cetuximab and/or panitumumab) have been approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Indeed, previous studies have identified mutations (MTs)/amplifications in RAS/RAF/MEK k